flortaucipir (18F)   Click here for help

GtoPdb Ligand ID: 9100

Synonyms: 18F-AV-1451 | [F-18]T807 | flortaucipir F-18 | LY-3191748 | Tauvid®
 Ligand is labelled  Ligand is radioactive
Compound class: Synthetic organic
Comment: Flortaucipir (18F) is an investigational PET imaging agent (diagnostic radiopharmaceutical) designed to visualise tau protein (MAPT; P10636) in Alzheimer's disease brains. Compare with the approved agent, florbetapir, used to visualise β-amyloid.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 41.57
Molecular weight 263.09
XLogP 3.22
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(cn1)c1ccc2c(c1)[nH]c1c2cncc1
Isomeric SMILES [18F]c1ccc(cn1)c1ccc2c(c1)[nH]c1c2cncc1
InChI InChI=1S/C16H10FN3/c17-16-4-2-11(8-19-16)10-1-3-12-13-9-18-6-5-14(13)20-15(12)7-10/h1-9,20H/i17-1
InChI Key GETAAWDSFUCLBS-SJPDSGJFSA-N
No information available.
Summary of Clinical Use Click here for help
In May 2020, the FDA approved flortaucipir F18 as a radioactive diagnostic agent for PET scans of patients being evaluated for Alzheimer's disease.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Binding to Tau protein permits the investigation of Tau pathology in neurodegenerative brain disease by in vivo neuroimaging.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02016560 Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects Phase 2/Phase 3 Interventional Avid Radiopharmaceuticals